Nektar registers Phase 3 "ZENITH AD-2" trial of rezpegaldesleukin in atopic dermatitis
- The study is designed to enroll 510 participants.
- The study is designed to enroll 510 participants.1 Its primary outcome differs by region: in the US, it measures the number of participants achieving an Investigator's Global Assessment score of 0 or 1 with at least a 2-point reduction from baseline at Week 24, on a scale from 0 to 4 where higher scores indicate more severe disease1, while outside the US, the endpoint is the number of participants reaching an IGA score of 0 or 1 at Week 24 on the same 0-to-4 scale1. The trial's status is listed as recruiting1, with a start date of 2026-08-07 and an estimated primary completion in June 20281.
Fact check notes
- Checker's noteThe claim that Nektar 'posted one new trial listing this week' is not supported by the source; the source only provides a first-posted date (2026-07-17) with no indication of relative timing to the report.
- Sentence removed
Nektar Therapeutics posted one new trial listing this week.
unsupported: The source gives a first-posted date but does not indicate the listing occurred 'this week' relative to the entry; this timing claim is fabricated. - Sentence removed
A Phase 3, randomized, double-blind, placebo-controlled study called "ZENITH AD-2" (NCT07711418) will test rezpegaldesleukin, also known as NKTR-358, as monotherapy in patients 12 years of age or older with moderate-to-severe atopic dermatitis.
a figure with no citation
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.